Faheem Hasnain
Faheem Hasnain's purchase track record
How the stock did after each of Faheem Hasnain's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/21/2024 | GOSS | $250K | +61.5% | +29.2% | +8.5% |
| 3/20/2023 | GOSS | $1.00M | +8.7% | -22.1% | +12.7% |
| 7/15/2022 | GOSS | $1000K | +9.8% | -78.9% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Transaction History
| GOSS | ▲ Buy | Grant | 280,000 | $0 | 1/2/2026 | View on chart |
| KURA | ▲ Buy | Option Exercise | 10,000 | $31K | 12/9/2025 | View on chart |
| KURA | ▼ Sell | Open Market | 10,000 | $110K | 12/9/2025 | View on chart |
| GOSS | ▲ Buy | Grant | 437,500 | $0 | 10/1/2025 | View on chart |
| GOSS | ▲ Buy | Open Market | 372,000 | $250K | 6/21/2024 | View on chart |
| GOSS | ▼ Sell | Open Market | 23,172 | $27K | 3/27/2024 | View on chart |
| GOSS | ▲ Buy | Grant | 540,176 | $983K | 7/24/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 440,500 | $504K | 3/22/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 269,389 | $322K | 3/21/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 168,683 | $174K | 3/20/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 138,696 | $1000K | 7/15/2022 | View on chart |
| GOSS | ▼ Sell | Open Market | 19,035 | $170K | 3/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.